IRIS
CAVALLI, GIULIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.074
AS - Asia 2.646
NA - Nord America 2.203
SA - Sud America 669
Continente sconosciuto - Info sul continente non disponibili 238
AF - Africa 62
OC - Oceania 1
Totale 8.893
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.080
RU - Federazione Russa 1.743
SG - Singapore 904
CN - Cina 845
BR - Brasile 540
SE - Svezia 404
IT - Italia 336
HK - Hong Kong 335
VN - Vietnam 260
DE - Germania 158
FR - Francia 134
BD - Bangladesh 89
GB - Regno Unito 83
FI - Finlandia 66
CA - Canada 63
AR - Argentina 61
IN - India 47
MX - Messico 31
ZA - Sudafrica 28
EC - Ecuador 25
AT - Austria 24
PL - Polonia 24
ID - Indonesia 23
NL - Olanda 22
TR - Turchia 22
ES - Italia 21
IQ - Iraq 21
IE - Irlanda 20
JP - Giappone 17
PK - Pakistan 14
CO - Colombia 12
VE - Venezuela 11
MA - Marocco 9
KE - Kenya 8
PY - Paraguay 8
UA - Ucraina 8
UZ - Uzbekistan 8
JM - Giamaica 7
PH - Filippine 7
CL - Cile 6
SA - Arabia Saudita 6
AE - Emirati Arabi Uniti 5
AZ - Azerbaigian 5
IR - Iran 5
MY - Malesia 5
NP - Nepal 5
PE - Perù 5
TN - Tunisia 5
BG - Bulgaria 4
EG - Egitto 4
DO - Repubblica Dominicana 3
IL - Israele 3
JO - Giordania 3
LT - Lituania 3
PA - Panama 3
RO - Romania 3
SV - El Salvador 3
TH - Thailandia 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
AL - Albania 2
AO - Angola 2
BE - Belgio 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
CZ - Repubblica Ceca 2
EU - Europa 2
GT - Guatemala 2
HN - Honduras 2
HR - Croazia 2
NI - Nicaragua 2
NO - Norvegia 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
XK - ???statistics.table.value.countryCode.XK??? 2
BB - Barbados 1
BH - Bahrain 1
BW - Botswana 1
CH - Svizzera 1
CU - Cuba 1
CY - Cipro 1
EE - Estonia 1
GA - Gabon 1
GR - Grecia 1
HT - Haiti 1
HU - Ungheria 1
KG - Kirghizistan 1
KH - Cambogia 1
KI - Kiribati 1
KR - Corea 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
MD - Moldavia 1
ME - Montenegro 1
MN - Mongolia 1
OM - Oman 1
PR - Porto Rico 1
PS - Palestinian Territory 1
RS - Serbia 1
Totale 8.658
Salva come PNG Salva come JPEG
Città #
Singapore 373
Moscow 355
Hong Kong 330
Dallas 292
Ashburn 283
San Jose 224
Shanghai 174
Hefei 119
New York 113
Lawrence 107
Princeton 107
Lauterbourg 103
Beijing 98
Ho Chi Minh City 94
Milan 94
Los Angeles 75
Munich 52
Hanoi 49
Santa Clara 48
São Paulo 48
Boardman 42
Helsinki 32
Nuremberg 32
Rome 25
Seattle 25
Turku 23
Denver 22
Rio de Janeiro 22
Atlanta 21
Orem 21
Montreal 20
Guangzhou 19
Chennai 18
Chicago 18
Dublin 18
London 18
Poplar 18
Cesano Boscone 17
Council Bluffs 17
Johannesburg 17
Warsaw 17
Da Nang 14
Houston 14
Brooklyn 13
Tokyo 13
Boston 12
Frankfurt am Main 12
Mexico City 12
Stockholm 12
Amsterdam 10
Brasília 10
Lappeenranta 10
Mumbai 10
Toronto 10
Ankara 9
Belo Horizonte 9
Bologna 9
Brescia 9
Hải Dương 9
Curitiba 8
Haiphong 8
Manchester 8
Pietra Ligure 8
The Dalles 8
Tianjin 8
Vienna 8
Guayaquil 7
Jakarta 7
Nairobi 7
Porto Alegre 7
Quito 7
Tashkent 7
Baghdad 6
Buenos Aires 6
Can Tho 6
Falkenstein 6
Istanbul 6
Lahore 6
Miami 6
Pune 6
Querétaro 6
Salvador 6
Uberlândia 6
Verona 6
Xi'an 6
Baku 5
Bauru 5
Buffalo 5
Campinas 5
Cape Town 5
Jiaxing 5
Phoenix 5
Quezon City 5
Saint Louis 5
San Francisco 5
Thái Bình 5
Vitória 5
Wolfhagen 5
Biên Hòa 4
Columbia 4
Totale 4.046
Salva come PNG Salva come JPEG
Nome #
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 210
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 182
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19 174
Adherence to the Mediterranean Diet in Italian Patients With Systemic Sclerosis: An Epidemiologic Survey 156
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study 150
Cardiovascular involvement in Erdheim-Chester diseases is associated with myocardial fibrosis and atrial dysfunction 137
Anakinra for patients with COVID-19: an updated systematic review and meta-analysis 132
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: An open-label cohort study 128
A bitter effect: thrombocytopenia induced by a quinidine-containing beverage 124
Maladaptive Autophagy in the Pathogenesis of Autoimmune Epithelitis in Sjögren's Syndrome 120
3D culture of Erdheim-Chester disease tissues unveils histiocyte metabolism as a new therapeutic target 117
A Novel Histiocytosis With Synovial and Skin Involvement 116
Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheim-Chester disease 114
Testosterone in males with COVID-19: A twelve-month cohort study 113
Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis 111
Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis: A Case Series 108
Assessing the role of pentraxin-3 in Takayasu's arteritis. Comment on: Plasma pentraxin-3 levels in patients with Takayasu's arteritis during routine follow-up. Alibaz-Oner F. et al 108
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study 107
Anakinra therapy for non-cancer inflammatory diseases 105
High-dose anakinra in addition to standard of care including corticosteroids in patients with severe COVID-19 treated with non-invasive ventilation 104
Mechanisms of hematopoietic clonal dominance in VEXAS syndrome 102
Myelomonocytic cells in giant cell arteritis activate trained immunity programs sustaining inflammation and cytokine production 102
Advances in potential targeted therapies for Erdheim-Chester disease 102
Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation 102
Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies 99
A virus-free cellular model recapitulates several features of severe COVID-19 98
Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience 97
DRUG RETENTION RATES OF BIOLOGICAL AGENTS IN ADULT ONSET STILL'S DISEASE IN THE PRE-CANAKINUMAB ERA 97
Immunosuppressive strategies in invasively ventilated ARDS COVID-19 patients 96
Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease 94
Autophagy and Protein Secretion 94
Interleukin 1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study 94
Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis 94
Autoimmune vitiligo is associated with gain-offunction by a transcriptional regulator that elevates expression of HLA-A∗02:01 in vivo 93
Oncogene-induced senescence in hematopoietic progenitors features myeloid restricted hematopoiesis, chronic inflammation and histiocytosis 93
BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. 91
An enlightening scan 88
Testosterone in males with COVID-19: A 7-month cohort study 88
Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series 87
Current treatment options and safety considerations when treating adult-onset Still’s disease 87
Anakinra for COVID-19: how to interpret elevations in serum liver enzymes 85
Biologic discontinuation strategies and outcomes in patients with rheumatoid arthritis 84
Aortic thrombosis secondary to clopidogrel-related thrombotic thrombocytopenic purpura 83
Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes 79
Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease 79
Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout 74
ROLE OF TRAINED IMMUNITY AND IMMUNOMETABOLISM IN THE PATHOGENESIS OF ERDHEIM-CHESTER DISEASE 73
Charcot's arthropathy of the spine 73
Anakinra for patients with COVID-19 – Authors' reply 73
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial 71
Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by Ferraccioli 70
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study 70
Interleukin-1 receptor blockade rescues myocarditis-associated end-stage heart failure 69
Cardiac magnetic resonance in systemic sclerosis patients with cardiac symptoms: do we really need it? 69
Interleukin-6 in ANCA-associated vasculitis: Rationale for successful treatment with tocilizumab 68
Tocilizumab for the Treatment of Myocardial Inflammation Shown by Cardiac Magnetic Resonance: Report of Two Cases and Rationale for Its Therapeutic Use 68
The anti-inflammatory cytokine interleukin-37 is an inhibitor of trained immunity 67
Impact of rare and common genetic variation in the interleukin-1 pathway on human cytokine responses 67
Immunometabolic activation of macrophages leads to cytokine production in the pathogenesis of KRAS-mutated histiocytosis 67
Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies 66
Treatment of Dilated Cardiomyopathy With Interleukin-1 Inhibition 65
QTc interval prolongation in Systemic Sclerosis: Correlations with clinical variables and arrhythmic risk 64
Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease 62
Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement 62
Methotrexate in refractory bilateral juvenile temporal arteritis: Report of a case 61
The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim-Chester disease 59
Myocarditis: An Interleukin-1-Mediated Disease? 59
Response to interleukin-1 inhibitors in 140 Italian patients with adult-onset still's disease: A multicentre retrospective observational study 59
Treating Experimental Arthritis with the Innate Immune Inhibitor IL-37 Reduces Joint and Systemic Inflammation 58
Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration, and improves exercise tolerance 57
Relationship Between Ventricular Arrhythmias, Conduction Disorders, and Myocardial Fibrosis in Patients With Systemic Sclerosis: The Role of Cardiac Magnetic Resonance 57
Definition of fibromyalgia severity: findings from a cross-sectional survey of 2339 Italian patients 56
Prevalence of Takayasu arteritis in young women with acute ischemic heart disease 56
Treating Pulmonary Silicosis by Blocking Interleukin 1 55
Tocilizumab in patients with multisystem Erdheim–Chester disease 55
Large-scale use of hydroxychloroquine for COVID-19 confirms safety, if not effectiveness 55
Diagnosing Erdheim-Chester disease 54
Gender differences in clinical presentation and vascular pattern in patients with Takayasu arteritis 54
Suppression of inflammation and acquired immunity by IL-37 54
Successful use of cyclosporin A and interleukin-1 blocker combination therapy in VEXAS syndrome: a single-center case series 53
The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases. 53
Large Vessel Vasculitis Affecting the Aorta and Its Branches in Relapsing Polychondritis: Case Series and Systematic Review of the Literature 53
Efficacy and safety of biological agents in adult-onset Still's disease 52
Priorities of biomedical research 52
Publications are not the finish line: Focusing on societal rather than publication impact 52
TUMOUR NECROSIS FACTOR-ALPHA AS A MASTER REGULATOR OF INFLAMMATION IN ERDHEIM-CHESTER DISEASE: RATIONALE FOR THE SUCCESSFUL TREATMENT OF TWO PATIENTS WITH INFLIXIMAB 51
Letter by Campochiaro et al regarding article, “Clinical features, management, and outcomes of immune checkpoint inhibitor–Related cardiotoxicity” 51
Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim-Chester Disease 49
Long-term retention rate of anakinra in adult onset Still’s disease and predictive factors for treatment response 49
Erdheim-Chester disease: An in vivo human model of Mϕ activation at the crossroad between chronic inflammation and cancer 49
Treating Life-Threatening Myocarditis by Blocking Interleukin-1 49
CARDIAC CINE MRI IN ERDHEIM-CHESTER DISEASE: DATA FROM A LARGE ITALIAN COHORT 48
Hypertrophic cardiomyopathy secondary to hepatitis C virus-related vasculitis 48
Charcot's arthropathy of the hip 48
MHC class II super-enhancer increases surface expression of HLA-DR and HLA-DQ and affects cytokine production in autoimmune vitiligo 47
CLINICAL PRESENTATION OF ERDHEIM-CHESTER DISEASE: DATA FROM A COHORT 47
Cardiovascular disease in patients with rheumatoid arthritis: impact of classic and disease-specific risk factors 47
Living with fibromyalgia during the COVID-19 pandemic: mixed effects of prolonged lockdown on the well-being of patients 47
In the limelight: AA amyloidosis exposes TNF receptor-1 associated periodic syndrome 47
Erratum: Management of adult-onset Still's disease with interleukin-1 inhibitors: Evidence- And consensus-based statements by a panel of Italian experts (Arthritis Res Ther (2019) 21:275 DOI: 10.1186/s13075-019-2021-9) 46
Totale 8.109
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.024
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 55.024
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022127 0 0 32 31 11 11 4 2 21 3 8 4
2022/2023678 240 157 53 5 12 81 27 52 33 2 8 8
2023/2024496 17 40 60 43 48 72 23 52 5 8 40 88
2024/20251.782 179 31 37 51 67 122 197 221 346 232 134 165
2025/20265.398 345 390 410 786 388 152 395 401 1.509 320 121 181
2026/2027278 269 9 0 0 0 0 0 0 0 0 0 0
Totale 8.893